Skip to content
NBlaz – Lifestyle
Author:
R.J. Walker & Co.
Iterion Therapeutics Expands Clinical Development of Tegavivint, a First-in-Class Wnt/β-Catenin Inhibitor, into Colorectal Cancer with First Patient Dosed
March 25, 2026
←
Previous Page
1
2